High-Level Overview
InCrowd, Inc. is a healthcare market research company founded in 2010, specializing in real-time data and insights for the life sciences industry through a cloud-based platform and a proprietary network of healthcare professionals.[1][4][5] Headquartered in Watertown, MA, it served over 100 life sciences firms, including 300+ brands and 18 of the top 20 pharmaceutical companies, by enabling agile micro-research that delivers results in hours via mobile responses from screened professionals.[1][5] The company solved the problem of slow, costly traditional market research by providing immediate, high-quality insights, but was acquired by SARORAS Private Capital in 2019 and later integrated into Konovo, an AI-enabled platform combining InCrowd with other research firms.[1][2]
Origin Story
InCrowd was founded in 2010 by entrepreneurs Janet Kosloff (CEO) and Diane Hayes (President) in Watertown, MA.[1][4] The duo pioneered real-time market research in life sciences, leveraging a sophisticated cloud platform and a global "Crowd" of healthcare professionals to disrupt traditional methods that took weeks.[1][5] Early traction came from awards and adoption by top pharma firms, culminating in the 2019 acquisition by SARORAS Private Capital, advised by Bowen Advisors, which positioned it for growth under new ownership.[1] By the early 2020s, InCrowd integrated into Konovo (formerly Apollo Intelligence), enhancing its AI capabilities alongside Survey Healthcare Global and GlocalMind.[2]
Core Differentiators
- Real-time insights platform: Combines cloud software with a proprietary network of screened healthcare professionals for results in hours, not weeks, via 70% mobile responses.[1][5]
- Scale and reach: Serves 300+ brands, including top pharma, with 3M+ answers from experienced professionals across 100+ life sciences firms.[1][5]
- Cost and speed efficiency: Enables agile micro-research at lower costs, used by 18 of top 20 pharma companies for faster decision-making.[1][5]
- AI evolution post-acquisition: Integrated into Konovo's AI-native platform to address industry fragmentation, improving efficiencies and insights quality.[2]
(Note: A separate entity, InCrowd Capital, operates as an angel network for SexTech and cannabis ventures, but lacks overlap with the primary healthcare-focused InCrowd.[3][6])
Role in the Broader Tech Landscape
InCrowd rode the trend of real-time data analytics in healthcare, accelerating insights amid rising demand for agile decision-making in life sciences R&D and market strategies.[1][5] Its timing aligned with pharma's shift to digital tools for faster go-to-market, countering traditional research delays amid regulatory pressures and competitive innovation races.[5] Market forces like mobile adoption (70% responses) and cloud scalability favored its model, influencing the ecosystem by setting standards for on-demand research now amplified in Konovo's AI platform tackling fragmentation.[2][5]
Quick Take & Future Outlook
Post-integration into Konovo, InCrowd's legacy powers AI-driven research streamlining, with expansion into global insights ecosystems likely.[2] Trends like AI-native platforms and deeper healthcare data integration will shape its path, evolving influence from pioneer to core component in unified research tech.[2] As life sciences demand instantaneous, quality data intensifies, Konovo—inheriting InCrowd's real-time edge—stands poised to dominate efficient insights delivery.[1][2]
